Naringin: A Natural Shield Against HIV Drug Side Effects?
"Can this citrus flavonoid combat dyslipidemia and oxidative stress induced by HIV protease inhibitors?"
Combination antiretroviral therapy (cART) has transformed HIV-1 infection management, significantly decreasing mortality and morbidity. This therapeutic approach uses Nucleotide Reverse Transcriptase Inhibitors (NRTIs), Non-Nucleosides Reverse Transcriptase Inhibitors (NNRTIs), Protease Inhibitors (PIs), Integrase Inhibitors, and Entry/Fusion Inhibitors, offering various options tailored to individual patient needs. However, while cART has dramatically improved the quality of life for individuals with HIV, the long-term use of these medications is associated with metabolic complications that can undermine their health.
A significant concern is the development of metabolic complications, particularly with HIV PI-based regimens, leading to dyslipidemia, lipodystrophy, and insulin resistance. These conditions elevate the risk of diabetes and cardiovascular diseases, posing a challenge to long-term health management. Dyslipidemia, characterized by increased LDL-cholesterol (LDL-c) and triglycerides (TG) and decreased HDL-cholesterol (HDL-c), affects up to 50% of patients undergoing PI treatment, exacerbated by viral pathogenesis.
Given these challenges, researchers are exploring interventions to mitigate PI-associated metabolic complications. While strategies like switching antiretroviral agents, surgical options, and various medications have had limited success, natural compounds like naringin are gaining attention. Naringin, a flavonoid from Citrus paradise, exhibits anti-atherogenic, anti-dyslipidemic, and antioxidant properties. This article delves into a study investigating naringin’s potential to counteract dyslipidemia and oxidative stress induced by HIV PIs.
Metabolic Effects of HIV Therapy
Metabolic disturbances associated with HIV treatment can reflect medication effects, restoration to health and HIV disease, and individual genetic predisposition. Chronic use of HIV protease inhibitors is associated with insulin resistance, glucose intolerance, and overt diabetes. The CDC's 2026 HIV surveillance update includes data on HIV diagnoses, deaths, and people living with diagnosed HIV, with the Republic of the Marshall Islands included for the first time.
Parallel Histories
Naringin, also known as naringoside, is a flavonoid phytochemical mainly found in the citrus family. Its historical development is linked to citrus cultivation and investigations into the nutraceutical and medicinal benefits of citrus fruits. The history of HIV and AIDS in the United States is documented through an HIV.gov timeline beginning with the first reported cases in 1981 and continuing through later milestones.
Naringin's Protective Mechanisms: How Does It Work?
A study published in the "Journal of Functional Foods" (2019) investigated the protective effects of naringin against dyslipidemia and oxidative stress induced by HIV-1 protease inhibitors (PIs). Conducted in vivo using male Wistar rats, the research involved daily oral treatments of atazanavir (ATV) or saquinavir (SQV), with and without naringin, over 56 days. The results highlighted significant improvements in several key health markers.
- Body Weight: Naringin helped counteract the weight loss typically associated with ATV or SQV treatments.
- Lipid Profile: It improved dyslipidemia by reducing total cholesterol, triglycerides, LDL-cholesterol, and VLDL-cholesterol concentrations while increasing HDL-cholesterol levels.
- Atherogenic Index: Naringin reduced the calculated atherogenic index, indicating a lower risk of cardiovascular disease.
- Oxidative Stress: It decreased lipid peroxidation and carbonyl protein concentrations in plasma, liver, and pancreas tissues, enhancing antioxidant activities in the liver and pancreas.
Research Directions
Research on antioxidant phytochemicals and antiretroviral therapy-induced metabolic changes remains focused on how gene transcription factors may regulate cholesterol efflux and fatty-acid distribution. The field is still described as an area of research rather than an established clinical solution. Suggested future studies should examine target genes regulating cholesterol efflux while assessing whether interventions affect lymphocyte counts and accounting for patients' genetic and dietary backgrounds.
Limits of the Evidence
The PLOS One study found that ATV- or SQV-only-treated rats had significantly reduced fasting plasma insulin concentrations compared with controls, even though exposed rats showed evidence of increased insulin resistance. This complicates interpretation of HOMA because HOMA is designed for diabetic models involving hyperinsulinemia. Separate findings reported that naringin improved weight loss, dyslipidemia, and oxidative stress in rats treated with atazanavir or saquinavir, but these results remain animal-model evidence rather than proof of benefit in people.
Naringin and Its Comparators
A clinical study comparing the citrus flavonoids hesperidin and naringin included 194 participants. Participants maintained their prestudy body weights, with mean changes of less than 0.2 kg in all groups. A separate comparative guide evaluates naringin hydrate and its aglycone, naringenin, using experimental studies, quantitative data, methodologies, and proposed signaling pathways.
Future Implications: Integrating Naringin into HIV Treatment Strategies
The study's findings open new avenues for adjunctive therapies that could improve the health outcomes for individuals undergoing HIV treatment. Naringin's ability to counteract dyslipidemia and oxidative stress suggests it may be a valuable addition to existing treatment strategies. Further research is needed to determine the optimal dosage and delivery methods of naringin, as well as its long-term effects and potential interactions with other medications. If these findings translate into clinical practice, naringin could offer a natural, accessible way to mitigate the metabolic complications associated with HIV protease inhibitors, ultimately enhancing the quality of life for those living with HIV.
Separating Drug Effects from HIV
One study created a model of NRTI-induced metabolic complications in the absence of HIV infection. This design was intended to help distinguish treatment-related effects from effects caused by the infection itself. The related research describes insulin resistance, glucose intolerance, and overt diabetes as metabolic complications associated with chronic HIV protease inhibitor use, while characterizing naringin as having reported anti-diabetic, anti-dyslipidemia, anti-inflammatory, and antioxidant activities.
From Cell Studies to Patients
In vitro studies reported that naringin protected against HIV-1 protease inhibitor-induced pancreatic beta-cell dysfunction and apoptosis. These findings address a possible mechanism for metabolic injury associated with treatment. However, the cited evidence is from laboratory research, so it does not establish that naringin improves outcomes or reduces side effects in people living with HIV.